What was the overall market valuation of the UK pain relief-medication market in 2024?

The overall market valuation was 6.72 USD Billion in 2024. Read More

What is the projected market valuation for the UK pain relief-medication market by 2035?

The projected valuation for 2035 is 14.66 USD Billion. Read More

What is the expected CAGR for the UK pain relief-medication market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 7.35%. Read More

Which segment of pain relief medications had the highest valuation in 2024?

In 2024, Non-Steroidal Anti-Inflammatory Drugs had the highest valuation at 2.01 USD Billion. Read More

What is the projected valuation for Acetaminophen in 2035?

The projected valuation for Acetaminophen in 2035 is 3.2 USD Billion. Read More

Which formulation type is expected to grow the most by 2035?

Tablets, with a projected valuation of 5.73 USD Billion in 2035, are expected to grow the most. Read More

What was the valuation of Opioids in 2024?

The valuation of Opioids in 2024 was 1.2 USD Billion. Read More

How does the valuation of Chronic Pain medications compare to Acute Pain medications in 2035?

In 2035, Chronic Pain medications are projected to be valued at 3.0 USD Billion, compared to 2.6 USD Billion for Acute Pain medications. Read More

Which key player is associated with the UK pain relief-medication market?

Key players include Johnson & Johnson, Pfizer Inc, and GlaxoSmithKline plc. Read More

What is the projected valuation for Injectable pain relief medications in 2035?

The projected valuation for Injectable pain relief medications in 2035 is 2.16 USD Billion. Read More

UK Pain Relief Medication Market

ID: MRFR/HC/49330-HCR

200 Pages

Nidhi Mandole

Last Updated: February 06, 2026

UK Pain Relief Medication Market Research Report By Medication Type (Non-Steroidal Anti-Inflammatory Drugs, Acetaminophen, Opioids, Adjuvant Analgesics), By Formulation Type (Tablets, Capsules, Liquid, Topical), By Route of Administration (Oral, Topical, Injectable, Transdermal) and By Therapeutic Area (Chronic Pain, Acute Pain, Postoperative Pain, Cancer Pain) - Growth & Industry Forecast 2025 To 2035

UK Pain Relief Medication Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Billion)
  1. 4.1.1 Non-Steroidal Anti-Inflammatory Drugs
  2. 4.1.2 Acetaminophen
  3. 4.1.3 Opioids
  4. 4.1.4 Adjuvant Analgesics
2. 4.2 Construction, BY Formulation Type (USD Billion)
  1. 4.2.1 Tablets
  2. 4.2.2 Capsules
  3. 4.2.3 Liquid
  4. 4.2.4 Topical
3. 4.3 Construction, BY Route of Administration (USD Billion)
  1. 4.3.1 Oral
  2. 4.3.2 Topical
  3. 4.3.3 Injectable
  4. 4.3.4 Transdermal
4. 4.4 Construction, BY Therapeutic Area (USD Billion)
  1. 4.4.1 Chronic Pain
  2. 4.4.2 Acute Pain
  3. 4.4.3 Postoperative Pain
  4. 4.4.4 Cancer Pain
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Johnson & Johnson (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer Inc (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bayer AG (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 GlaxoSmithKline plc (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AbbVie Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis AG (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi S.A. (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca PLC (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY TYPE
3. 6.3 UK MARKET ANALYSIS BY FORMULATION TYPE
4. 6.4 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 UK MARKET ANALYSIS BY THERAPEUTIC AREA
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Billion)
14. 6.14 CONSTRUCTION, BY FORMULATION TYPE, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
16. 6.16 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
18. 6.18 CONSTRUCTION, BY THERAPEUTIC AREA, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Construction Market Segmentation

Construction By Type (USD Billion, 2025-2035)

Non-Steroidal Anti-Inflammatory Drugs
Acetaminophen
Opioids
Adjuvant Analgesics

Construction By Formulation Type (USD Billion, 2025-2035)

Tablets
Capsules
Liquid
Topical

Construction By Route of Administration (USD Billion, 2025-2035)

Oral
Topical
Injectable
Transdermal

Construction By Therapeutic Area (USD Billion, 2025-2035)

Chronic Pain
Acute Pain
Postoperative Pain
Cancer Pain

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”